Abstract
We thank Dr. Faber and colleagues for their reply. We agree that intravenous immunoglobulin therapy (IVIG) is not a remedy for all patients with idiopathic small fiber neuropathy (I-SFN). However, the study population was nonrepresentative of clinical practice, given the 75% screening exclusion of patients with SFN. Furthermore, the clinical relevance is limited because the reasons for exclusion were not provided, other than the 16% exclusion for autoimmune comorbidities.1 These are precisely the patients who should be considered for immunotherapy.2
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
